ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer

The goal of this clinical trial is to assess the safety and efficacy of ANO31905 in combination with chemotherapy as the first-line treatment for subjects with CLDN18.2-positive locally advanced unresectable or metastatic pancreatic cancer.

Trial Details

NCT ID
NCT07444541
Phase
PHASE1 / PHASE2
Sponsor
Anova Innovation Limited
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • ANO31905
  • AG [gemcitabine+nab-paclitaxel]
  • mFOLFIRINOX [Oxaliplatin+irinotecan+leucovorin+fluorouracil]
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Plantation, Florida, United States|26.13421,-80.23184
  • San Antonio, Texas, United States|29.42412,-98.49363

Key Eligibility Criteria

  • Patients voluntarily participate in the study and sign the written ICF;
  • Males or females aged ≥ 18 at the time of signing the ICF;
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;
  • Expected survival ≥ 3 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →